The stock will trade on Phase 2a and Phase 1 topline data catalysts this summer, not on Q1 financials. Watch for sweat chloride data from PreciSION CF, a clinically meaningful reduction would validate SION-719's mechanism and likely drive a re-rating. The 88% analyst buy rating and $2.1B market cap already price in some optimism; a data miss would be severely punished given the binary nature of the readout.
SION drugs
SION drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $40.94entry
- T+1 · 6mo ago +5.32%α +4.75% · $43.12
- T+5 · 6mo ago −4.15%α −4.23% · $39.24
- T+20 · 5mo ago −16.88%α −15.15% · $34.03
- T+60 · 3mo ago +21.18%α +16.79% · $49.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16.5M a year ago on higher R&D and G&A spending. The key catalyst is the on-track summer 2026 topline data from the Phase 2a PreciSION CF trial and Phase 1 dual-combination trial, which will determine whether SION-719 can expand CF treatment options. Cash of $289.9M funds operations into 2028, removing near-term dilution risk.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.60 vs consensus -$0.62 (3.2% beat)
- Net loss widened to $26.8M from $16.5M YoY on higher R&D ($19.0M vs $13.7M) and G&A ($10.6M vs $6.0M)
- Phase 2a PreciSION CF trial of SION-719 enrollment completed; topline data expected summer 2026
- Phase 1 dual-combination trial of SION-451 with SION-2222 and SION-109 on track for summer 2026 topline data
- Cash, cash equivalents and marketable securities $289.9M; expected to fund operations into 2028
- No revenue reported (pre-commercial biotech)
Financial Impact
Net loss of $26.8M in Q1 2026 vs $16.5M in Q1 2025; cash burn rate ~$10M/month
Risk Factors
- Phase 2a topline data could fail to show clinically meaningful sweat chloride reduction, undermining the NBD1 stabilizer thesis
- Cash burn rate increased 62% YoY; if data disappoints, financing risk emerges despite current runway into 2028
- Insider selling of $31.7M in last 30 days may signal lack of confidence ahead of data readout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292667 |
Track record
22 reports on SION
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers